|
MORF4L2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
2.1955000040208E-09 |
| Normal-vs-Stage3 |
6.66133814775094E-16 |
| Normal-vs-Stage4 |
5.19584375524573E-14 |
| Stage1-vs-Stage2 |
3.624000E-01 |
| Stage1-vs-Stage3 |
5.121500E-02 |
| Stage1-vs-Stage4 |
5.937200E-03 |
| Stage2-vs-Stage3 |
6.572600E-01 |
| Stage2-vs-Stage4 |
3.081400E-01 |
| Stage3-vs-Stage4 |
4.012000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.77697872977478E-13 |
| Normal-vs-AfricanAmerican |
8.641100E-04 |
| Normal-vs-Asian |
2.66379995839117E-09 |
| Caucasian-vs-AfricanAmerican |
1.572310E-02 |
| Caucasian-vs-Asian |
4.238200E-01 |
| AfricanAmerican-vs-Asian |
1.502420E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.369600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.70563563273163E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(81-100Yrs) |
3.597500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.601570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.477700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.314000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.613830E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.216200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.220000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.132820E-01 |
| Classical-VS-Follicular |
9.476200E-01 |
| Classical-VS-Other |
5.445200E-01 |
| Classical-VS-Normal |
7.76569919480607E-11 |
| Tall-VS-Follicular |
1.291000E-01 |
| Tall-VS-Other |
8.271600E-01 |
| Tall-VS-Normal |
1.29849464514109E-11 |
| Follicular-VS-Other |
6.423000E-01 |
| Follicular-VS-Normal |
3.29039995250469E-09 |
| Other-VS-Normal |
1.239570E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.7715611723761E-16 |
| Normal-vs-N1 |
7.67252927857953E-12 |
| N0-vs-N1 |
5.726600E-01 |
|
|
